Royal Bank of Canada
CMPX icon

Royal Bank of Canada’s Compass Therapeutics CMPX Stock Holding History

Royal Bank of Canada’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
6
-3,815
-100% -$22K ﹤0.01% 7188
2025
Q4 		$21K Sell
3,821
-1,697,106
-100% -$7.84M ﹤0.01% 6008
2025
Q3 		$5.95M Buy
1,700,927
+1,549,785
+1,025% +$4.9M ﹤0.01% 2531
2025
Q2 		$393K Buy
151,142
+141,583
+1,481% +$292K ﹤0.01% 4647
2025
Q1 		$18K Sell
9,559
-5,784
-38% -$15.4K ﹤0.01% 5953
2024
Q4 		$23K Buy
15,343
+4,192
+38% +$6.96K ﹤0.01% 6052
2024
Q3 		$20K Sell
11,151
-21,507
-66% -$26.8K ﹤0.01% 6100
2024
Q2 		$33K Buy
32,658
+30,588
+1,478% +$44.7K ﹤0.01% 5841
2024
Q1 		$4K Sell
2,070
-27,018
-93% -$46.7K ﹤0.01% 6488
2023
Q4 		$45K Buy
29,088
+9,338
+47% +$16.2K ﹤0.01% 6041
2023
Q3 		$38K Buy
19,750
+7,000
+55% +$17.3K ﹤0.01% 5917
2023
Q2 		$41K Buy
12,750
+11,793
+1,232% +$37K ﹤0.01% 5866
2023
Q1 		$3K Buy
+957
New +$3.76K ﹤0.01% 6679
2022
Q4 		– Sell
-675
Closed -$2K – 7278
2022
Q3 		$2K Buy
675
+447
+196% +$1.24K ﹤0.01% 6994
2022
Q2 		$1K Sell
228
-555
-71% -$1.21K ﹤0.01% 7100
2022
Q1 		$1K Buy
+783
New +$1.62K ﹤0.01% 7583

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's CMPX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Compass Therapeutics (CMPX) stake by 100% in Q1 2026, selling an estimated $22K and leaving 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7188.

Royal Bank of Canada first reported a position in CMPX in Q1 2022 and has held it in 16 quarters since. The position peaked at $5.95M in Q3 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Royal Bank of Canada held 6 shares of Compass Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 3,815 Compass Therapeutics shares in Q1 2026, an estimated $22K.
  • Compass Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7188 holding.
  • Royal Bank of Canada first reported a position in Compass Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • Royal Bank of Canada's Compass Therapeutics position peaked at $5.95M in Q3 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.